Please login to the form below
Ionis Pharmaceuticals
This page shows the latest Ionis Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
GSK’s Ionis-partnered hepatitis B drug hits the mark in phase 2
GlaxoSmithKline has announced positive results from a phase 2a study of its Ionis-partnered antisense medicine for chronic hepatitis B virus (CHB) infection. ... As part of the licensing deal, Ionis is set to receive fees and milestone payments of up to
Latest news
-
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
FDA surprises Akcea and Ionis with rejection of Waylivra. Akcea Therapeutics, a subsidiary of Ionis Pharmaceuticals, has been knocked back by a surprise rejection via a Complete Response Letter (CRL) from ... However Ionis faces stiff competition from
-
Alnylam takes off on APOLLO trial results
Alnylam's success in the phase III trial proved to be a dampener for Ionis Pharmaceuticals, which is developing antisense-based drug inotersen for this type of familial amyloid polyneuropathy (FAP). ... The company shares fell yesterday on the APOLLO
-
Safety issues dampen enthusiasm for Akcea's volanesorsen
But Ionis Pharmaceuticals' subsidiary presses on with filing plans. Akcea Therapeutics says it plans to file for approval of its drug for rare disease familial chylomicronaemia syndrome (FCS) later this year ... There was also a reduction in pancreatitis
-
Merck & Co wins hepatitis C patent dispute with Gilead
The jury in the lawsuit upheld Merck's claim that Gilead's sofosbuvir - which features in its massive-selling Sovaldi and Harvoni HCV drugs - infringes two patents it holds alongside Ionis ... Pharmaceuticals (formerly known as Isis Pharma).
-
Isis renamed Ionis to sidestep militant association
Says the move should avoid any 'distraction' to its business. Isis has announced a change in name to Ionis Pharmaceuticals in a bid to avoid any association with the Islamic State ... Ionis "is an original name that the company has chosen to represent
More from news
Approximately 1 fully matching, plus 5 partially matching documents found.
Latest Intelligence
-
Where next in Alzheimer’s disease R&D?
The big biotech is testing its own BIIB092 in early Alzheimer’s patients and has an option to develop an Ionis Pharmaceuticals’ antisense drug designed to reduce production of tau in ... Meanwhile, Karuna Pharmaceuticals has raised $42m to resurrect
-
Deal Watch October 2018
Tregs) while preserving effector T‐cells (Teffs). Acquisition. $759m. Ionis Pharmaceuticals/. Roche. ... US. US and Canada only. # US and EU. Roche’s collaboration with Ionis Pharmaceuticals has a headline of $760m, $1m more than the Tusk deal.
-
Deal Watch February 2017
Ionis Pharmaceuticals and Bayer entered into a licence in May 2015 for IONIS-FXIRx, an antisense therapeutic designed to reduce the production of Factor XI for the prevention of thrombosis. ... Licence, collaboration. 237.5. Portola
-
Deal Watch May 2016
This month GSK elected not to currently proceed with its option to Ionis Pharmaceuticals' IONIS-TTRrx, which was about to enter into phase 3 clinical development. ... The knock on effect for Ionis shares was a dip by a significant 40%.
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Gilead agrees $21bn buyout of Immunomedics
- Trials resume for AZ/Oxford University COVID-19 vaccine
- Regeneron launches phase 3 COVID-19 antibody trial in the UK
- First patients dosed with COVID-19 vaccine from SpyBiotech and Serum Institute of India
- Positive COPD data for Synairgen's SNG001 supports COVID-19 programme
- Roche’s Ocrevus boasts positive long-term data in MS
- Envision Pharma Group scoops two Silvers at the PM Society Digital Awards 2020
- Alone we can do so little, together we can do so much
- What can't we afford to treat anymore?
- OPEN VIE is awarded a Bronze Award at the PM Society Digital Awards 2020
- BioNTech bolsters COVID-19 vaccine capacity with Novartis deal
- Moderna inks R&D agreements with Vertex and Chiesi
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- Alone we can do so little, together we can do so much
- Collaboration is at the heart of successful patient engagement and effective healthcare provision. But in such a complex, nuanced network, true collaborations are rare. So how can we, as an...
- 7 important considerations for creating an inclusive clinical trial website
- You might have noticed that all of us here at COUCH Health are big advocates for taking action to improve diversity and inclusion in the world of clinical research. ‘Taking...
- Route 66: can remote working put two-thirds of us back on the road to engaged employment?
- Pre-pandemic, 66% of the world’s workforce weren’t engaged in their jobs – Chris Ross examines how the rush to remote working has impacted employee engagement...
Quick links
Infographics
